Business context and reporting period
This is Catalyst Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2017—not a filing identified in its text as GYRE Therapeutics, Inc. The filing covers the full year, not a standalone fourth quarter. Catalyst was a clinical-stage biopharmaceutical company focused primarily on hemophilia therapies; it had no products approved for sale and generated no product-sales revenue.
Financial performance and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Contract revenue | $1.018 million | $0.399 million |
| Research and development expense | $12.847 million | $11.555 million |
| General and administrative expense | $9.993 million | $9.262 million |
| Operating loss | $21.822 million | $20.418 million |
| Net loss | $21.561 million | $16.945 million |
| Cash used in operating activities | $19.940 million | $18.472 million |
- Revenue was entirely collaboration-related, principally from ISU Abxis; there were no product sales. Gross margin is not meaningfully presented for a company at this development stage.
- At year-end, cash and cash equivalents were $14.472 million and short-term investments were $17.971 million, totaling approximately $32.4 million. Restricted cash was an additional $5.333 million. Total assets were $39.513 million; total liabilities were $8.739 million, including $5.085 million of redeemable convertible notes.
- Cash provided by financing activities was $35.4 million, largely from 2017 equity offerings. The remaining notes were repaid at maturity in February 2018 using restricted cash.
- After year-end, a February 2018 common-stock offering generated approximately $106.7 million in net proceeds. This materially strengthened liquidity after the balance-sheet date; the company stated that available resources were expected to fund operations for at least 12 months from the filing date.
- The filing reports no conventional funded debt apart from the redeemable notes. No off-balance-sheet arrangements were reported.
Changes versus the prior comparable year
- Contract revenue increased by $0.619 million, or 155%, mainly from ISU Abxis milestone payments and related recognition.
- R&D expense rose 11%, primarily because of higher manufacturing and external research costs, partly offset by lower personnel and facility costs following the 2016 workforce reduction.
- G&A expense increased 8%. Operating loss widened 7%, while net loss increased 27%, in part because 2016 included gains from asset sales and a change in the fair value of a derivative liability.
- Operating cash use increased to $19.940 million from $18.472 million. The company continued substantial equity financing; common shares outstanding increased from 801,756 at year-end 2016 to 6,081,230 at year-end 2017, with additional shares issued after year-end.
Outlook, commentary, risks and unusual items
- Pipeline and milestones: Marzeptacog alfa (activated), a subcutaneous Factor VIIa candidate for hemophilia A or B with inhibitors, was in an enrolling Phase 2/3 trial; interim data was expected in July 2018. CB 2679d/ISU304, a Factor IX candidate for hemophilia B, completed enrollment in a South Korean Phase 1/2 trial. Top-line data presented in February 2018 reported a median Factor IX activity level of 16% after six daily subcutaneous doses in five subjects in Cohort 5; a Phase 2b trial was planned for the third quarter of 2018. These early results are based on small patient groups and are not proof of efficacy or safety in larger trials.
- Cost outlook: Management expected 2018 R&D expense to increase materially, mainly due to clinical-trial and manufacturing costs for the two lead candidates; G&A expense was expected to be similar to 2017. The company expected continued operating losses for several years.
- Funding and commitments: Despite the post-year-end financing, development plans require substantial capital and future financing is not assured. Pfizer may receive up to $17.5 million in clinical, regulatory and commercial milestone payments and a single-digit royalty on covered product sales; Catalyst paid a $1 million milestone in February 2018. Remaining 2017 year-end AGC obligations for MarzAA were approximately $0.7 million; a February 2018 manufacturing statement of work for CB 2679d/ISU304 involved approximately $5.6 million, subject to work-stage completion.
- Key risks: The principal programs remain investigational, with risks of trial failure, adverse events or neutralizing antibodies, enrollment delays, manufacturing setbacks, regulatory rejection, competition, and inadequate reimbursement. The company relies on third parties for manufacturing and clinical activities. It also disclosed a European patent and related foreign counterparts with claims that may read on marzeptacog alfa (activated); an appeal was pending.
- Other items: The 2017 net loss attributable to common stockholders included a $3.951 million noncash deemed dividend related to the Series A preferred-stock beneficial conversion feature. The filing reported a strategic research collaboration with Mosaic Biosciences for anti-C3 products for dry AMD; the CEO and a director also served on Mosaic’s board, and the transaction was reviewed by disinterested directors and approved by the audit committee. The independent auditor gave an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective, but the auditor did not provide an ICFR opinion.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Catalyst Biosciences, Inc. (NASDAQ: CBIO), despite the request metadata naming GYRE Therapeutics, Inc.
- Check subsequent filings for actual MarzAA interim and later-stage trial results, and for the design, timing and results of the planned CB 2679d/ISU304 Phase 2b trial.
- Reconcile current cash, cash burn and runway after the February 2018 offering, note repayment, and later development and manufacturing spending.
- Review dilution from the 2017 and 2018 offerings, preferred-stock conversions, warrant exercises and outstanding options.
- Track milestone and royalty obligations to Pfizer and ISU Abxis, manufacturing commitments to AGC, and the status of the disclosed patent appeal.